ATE323160T1 - Opioid antagonisten und verfahren zu deren anwendung - Google Patents

Opioid antagonisten und verfahren zu deren anwendung

Info

Publication number
ATE323160T1
ATE323160T1 AT96928209T AT96928209T ATE323160T1 AT E323160 T1 ATE323160 T1 AT E323160T1 AT 96928209 T AT96928209 T AT 96928209T AT 96928209 T AT96928209 T AT 96928209T AT E323160 T1 ATE323160 T1 AT E323160T1
Authority
AT
Austria
Prior art keywords
peptide
ofq
ligands
ofqr
methods
Prior art date
Application number
AT96928209T
Other languages
German (de)
English (en)
Inventor
Judith E Grisel
Jeffrey S Mogil
David K Grandy
James R Bunzow
Olivier Civelli
Rainer Klaus Reinscheid
Hans-Peter Nothacker
Frederick James Monsma
Original Assignee
Univ Oregon Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/514,451 external-priority patent/US5837809A/en
Application filed by Univ Oregon Health Sciences filed Critical Univ Oregon Health Sciences
Application granted granted Critical
Publication of ATE323160T1 publication Critical patent/ATE323160T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96928209T 1995-08-11 1996-08-12 Opioid antagonisten und verfahren zu deren anwendung ATE323160T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/514,451 US5837809A (en) 1995-08-11 1995-08-11 Mammalian opioid receptor ligand and uses
US08/553,058 US5821219A (en) 1995-08-11 1995-11-03 Opioid antagonists and methods of their use

Publications (1)

Publication Number Publication Date
ATE323160T1 true ATE323160T1 (de) 2006-04-15

Family

ID=27058205

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96928209T ATE323160T1 (de) 1995-08-11 1996-08-12 Opioid antagonisten und verfahren zu deren anwendung

Country Status (8)

Country Link
US (1) US5821219A (enExample)
EP (1) EP0843726B1 (enExample)
JP (1) JP3868494B2 (enExample)
AT (1) ATE323160T1 (enExample)
AU (1) AU728001B2 (enExample)
CA (1) CA2229126A1 (enExample)
DE (1) DE69636037D1 (enExample)
WO (1) WO1997007212A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2206192A1 (en) 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
EP0813065A3 (en) * 1996-06-13 1998-07-22 F. Hoffmann-La Roche Ag Modulation of LC132 (opioid-like) receptor function
AU8333998A (en) * 1997-07-15 1999-02-10 Novo Nordisk A/S New use of nociceptin
AU8334298A (en) * 1997-07-15 1999-02-10 Novo Nordisk A/S Nociceptin analogues
US5929035A (en) * 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
GB9815618D0 (en) * 1998-07-18 1998-09-16 Univ Manchester Treatment of dyskinesia
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
US6582457B2 (en) * 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US6849449B2 (en) * 2001-03-01 2005-02-01 Regents Of The University Of Michigan Orphanin FQ receptor nucleic acids
JP2005502619A (ja) * 2001-07-02 2005-01-27 オメロス コーポレイション オピオイドレセプター様レセプター１アゴニストと交替でオピオイドレセプターアゴニストを投与することを含む、痛覚脱失を生成するための方法
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
WO2003030828A2 (en) * 2001-10-09 2003-04-17 Synvax, Inc. Nociceptin-based analgesics
WO2003093294A2 (en) * 2002-04-29 2003-11-13 Euro-Celtique S.A. Conformationally constrained peptides that bind the orl-1 receptor
WO2004013292A2 (en) * 2002-08-02 2004-02-12 Incyte Corporation Extracellular messengers
KR20050043935A (ko) 2002-09-09 2005-05-11 얀센 파마슈티카 엔.브이. Ｏｒｌ-1 수용체 매개 장애의 치료에 유용한 하이드록시 알킬 치환된 1,3,8-트리아자스피로[4.5]데칸-4-온 유도체
SI2368553T1 (sl) 2003-04-08 2015-05-29 Progenics Pharmaceuticals, Inc. Farmacevtske formulacije, vsebujoče metilnatrekson
US7173010B2 (en) * 2003-05-19 2007-02-06 Regents Of The University Of Michigan Orphanin FQ receptor
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
JP2008542375A (ja) 2005-06-02 2008-11-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｏｒｌ−１受容体モジュレーターとして有用な新規３−スピロ環式インドリル誘導体
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
KR20090083954A (ko) 2006-11-28 2009-08-04 얀센 파마슈티카 엔.브이. 3-(3-아미노-2-(ｒ)-하이드록시프로필)-1-(4-플루오로페닐)-8-(8-메틸나프탈렌-1-일메틸)-1,3,8-트리아자-스피로[4.5]데칸-4-온의 염
PT2565195E (pt) 2007-03-29 2015-07-28 Wyeth Llc Antagonistas e receptor opióide periférico e respectivas utilizações
CA2945356C (en) 2007-03-29 2021-03-23 Progenics Pharmaceuticals, Inc. (r)-n-methylnaltrexone bromide and pharmaceutical compostitions therof useful as peripheral .mu. opioid receptor antagonist
PL2137191T3 (pl) 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
CA2683598C (en) 2007-04-09 2015-11-17 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
US8278442B2 (en) 2007-05-22 2012-10-02 Prosidion Limited Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders
US8063247B2 (en) 2007-09-07 2011-11-22 Prosidion Limited Bicyclic aryl and heteroaryl receptor modulators
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
RU2492482C1 (ru) * 2012-10-08 2013-09-10 Игорь Петрович Папышев Способ диагностики причины смерти от интоксикации наркотическими веществами группы опиатов

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582820A (en) * 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5017689A (en) * 1989-07-06 1991-05-21 Arizona Technology Development Corporation Dynorphin analogs specific for kappa opioid receptors
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US6235496B1 (en) * 1993-03-08 2001-05-22 Advanced Research & Technology Institute Nucleic acid encoding mammalian mu opioid receptor

Also Published As

Publication number Publication date
JP2001520634A (ja) 2001-10-30
JP3868494B2 (ja) 2007-01-17
EP0843726B1 (en) 2006-04-12
EP0843726A1 (en) 1998-05-27
US5821219A (en) 1998-10-13
WO1997007212A1 (en) 1997-02-27
DE69636037D1 (de) 2006-05-24
AU728001B2 (en) 2001-01-04
AU6776996A (en) 1997-03-12
CA2229126A1 (en) 1997-02-27

Similar Documents

Publication Publication Date Title
ATE323160T1 (de) Opioid antagonisten und verfahren zu deren anwendung
Heyman et al. Modulation of μ-mediated antinociception by δ agonists: characterization with antagonists
Swain et al. Endogenous opioids accumulate in plasma in a rat model of acute cholestasis
Bigoni et al. Nociceptin/orphanin FQ receptor ligands
Suh et al. Intrathecal beta-funaltrexamine antagonizes intracerebroventricular beta-endorphin-but not morphine-induced analgesia in mice.
Narita et al. Evidence for the existence of the β-endorphin-sensitive “ε-opioid receptor” in the brain: The mechanisms of ε-mediated antinociception
Khroyan et al. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/μ-opioid receptor agonists
Kastin et al. Tyr-MIF-1 acts as an opiate antagonist in the tail-flick test
Ogawa et al. Characteristics of thyrotropin releasing hormone (TRH) receptors in rat brain
SHAHABI et al. Murine splenocytes express a naloxone-insensitive binding site for β-endorphin
Barg et al. Evidence for the implication of phosphoinositol signal transduction in μ‐opioid inhibition of DNA synthesis
Jinsmaa et al. Differentiation of opioid receptor preference by [Dmt1] endomorphin-2-mediated antinociception in the mouse
Bhargava et al. Kappa opioid receptor activity in spontaneously hypertensive rats.
Gerstberger et al. Dynorphin 1–8 binds to opiate kappa receptors in the neurohypophysis
Gherardi et al. Neuropeptide FF receptors of mouse olfactory bulb: binding properties and stimulation of adenylate cyclase activity
Varani et al. Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships
Salvadori et al. Structure–activity studies on nociceptin/orphanin FQ: from full agonist, to partial agonist, to pure antagonist
Beinborn et al. Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties
Sibilia et al. Evidence for a Role of the GHS‐R1a Receptors in Ghrelin Inhibition of Gastric Acid Secretion in the Rat
Wu et al. Acute antinociceptive tolerance and asymmetric cross-tolerance between endomorphin-1 and endomorphin-2 given intracerebroventricularly in the mouse
Rothman et al. Ligand selectivity of cloned human and rat opioid mu receptors
STOJILKOVIC et al. Opiate receptor subtypes in the rat hypothalamus and neurointermediate lobe
WO1991000736A1 (en) Dynorphin analogs specific for kappa opioid receptors
Han et al. Synergistic effect of cholecystokinin octapeptide and angiotensin II in reversal of morphine induced analgesia in rats
Tsujii et al. Effects of food deprivation and high fat diet on opioid receptor binding in rat brain

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties